Pharmacovigilance – Products

Most comprehensive and ethnically diverse genomic coverage on a high throughput microarray delivers multi-disease and pharmacogenomic research analysis across global populations.

This article explores how scientists are tackling the challenges and intensifying efforts to develop mRNA therapeutics for different diseases.

SOLASCURE Ltd, a biotechnology company developing a hydrogel containing tarumase (provisional INN), a recombinant enzyme derived from maggots, and which aims to accelerate wound debridement and contribute to wound bed preparation & healing.

PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822.

Encouraging preliminary data from the ongoing DIPG clinical study to be presented at the 2023 Society for Neuro-Oncology Annual Meeting in Vancouver.

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Armis Biopharma, Inc. announced that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

A team of scientists have developed a protocol for the fabrication of a 3D microfluidic neuromuscular platform that can be used to model Motor Neuron Diseases (MND’s).

Extended long-term collaboration to provide significant additional bioconjugation capacity for commercialization of antibody-drug conjugates (ADCs) for use against hard-to-treat cancers.